There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on Aquantia Corp (NYSE: AQ) and Bioxcel Therapeutics Inc (NASDAQ: BTAI) with bullish sentiments.
Aquantia Corp (NYSE: AQ)
Needham analyst Quinn Bolton maintained a Buy rating on Aquantia Corp (NYSE: AQ) today and set a price target of $20. The company’s shares closed yesterday at $11.59.
Bolton said:
“and VP of Marketing, Amir Bar-Niv, presented at Tech Day. The presentation highlighted the need for reliable, high-speed connectivity solutions in automotive applications and provided details around the significant market opportunity for Ethernet solutions. Driven by increasing levels of autonomy, automotive semiconductor revenue exceeded $30bn in 2017 and is forecast to be the fastest growing semiconductor end-market through 2021 with a 10.8% CAGR. As part of this growing TAM, AQ highlighted a potential 400MM port opportunity for Ethernet. As the market leader and only company currently sampling Multi-Gig Ethernet solutions for automotive applications, we came away from the presentation incrementally more positive on AQ. $20 PT .”
According to TipRanks.com, Bolton is a top 100 analyst with an average return of 17.4% and a 69.3% success rate. Bolton covers the Consumer Goods sector, focusing on stocks such as MACOM Technology Solutions Holdings Inc, Sequans Communications S A, and Quantenna Communications.
Aquantia Corp has an analyst consensus of Moderate Buy, with a price target consensus of $20.
See today’s analyst top recommended stocks >>
Bioxcel Therapeutics Inc (NASDAQ: BTAI)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Bioxcel Therapeutics Inc (NASDAQ: BTAI), with a price target of $25. The company’s shares closed yesterday at $10.98.
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of -0.4% and a 40.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Bioxcel Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $20.40.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
